Haffkine Considers Private Partner For DPT Vaccine Production Amid Funding Crisis
Published on: April 10, 2026, 1:33 a.m. | Source: Free Press Journal
Haffkine Bio-Pharmaceutical Corporation has floated an EOI to transfer DPT vaccine production to a private player, with Mumbai-based Reliance Life Sciences reportedly interested. Officials cite outdated facilities and lack of funding for 24 years. The move retains Haffkine ownership and royalties, while vaccines continue under its name. No final decision has been made yet.
